BRISTOL MYERS SQUIBB CO
About BRISTOL MYERS SQUIBB CO
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $48.2B
- Net income
- $7.1B
- Total assets
- $90.0B
- Market cap
- $116.9B
- Gross margin
- 71.1%
- Operating margin
- 19.4%
- Net margin
- 14.6%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $48.2B
- Cost of revenue
- $13.9B
- Gross profit
- $34.3B
- Operating expenses
- $24.9B
- Operating income
- $9.3B
- Income tax
- $2.3B
- Net income
- $7.1B
- EPS (basic)
- $3.47
- EPS (diluted)
- $3.46
Balance sheet
- Total assets
- $90.0B
- Current assets
- $29.4B
- Total liabilities
- $71.5B
- Current liabilities
- $23.4B
- Shareholders’ equity
- $18.5B
Cash flow
- Operating cash flow
- $14.2B
- Investing cash flow
- -$4.1B
- Financing cash flow
- -$10.3B
- Net cash flow
- -$129.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $116.9B
- P/E ratio
- 16.1
- EPS (diluted)
- $3.46
- Dividend yield
- 4.53%
- Shares outstanding
- 2.1B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 23, 1952
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $7.1B in FY2025.
- Revenue grew 4% from FY2021 to FY2025.
- Gross margin of 71.1%, net margin 14.6%.
- Trading 11% below its 52-week high.
- Pays a dividend yielding about 4.53% annually.
- Valued at a price-to-earnings (P/E) ratio of 16.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review BRISTOL MYERS SQUIBB CO.
Write a review
News about BRISTOL MYERS SQUIBB CO
News & sentiment via Polygon.io
